Orbis Research: Statistical Analysis for Global Celiac Disease (CD) Market capacity, production, production value, cost/profit, supply/demand and import/export. The report will assist reader with better understanding and decision making.
Celiac Disease (CD) Market Insights, Epidemiology and Market Forecast-2023 report provides an overview of the disease and global market size of the Celiac Disease for the 6MM (United States and EU5 countries (France, Germany, Italy, Spain and UK)). It also includes global historical and forecasted epidemiological data for the diagnosed prevalent cases of Celiac Disease from 2013-2023.
Attractive Discount Details on Purchase of This Report:
Get Flat 15% on Single User License, Flat 25% on Site License & Flat 30% on Enterprise Licence
Offer Last 30th June
Get a PDF Sample of Report at: http://www.orbisresearch.com/contacts/request-sample/209364 .
Celiac disease is a genetic autoimmune disease where the indigestion of gluten leads to damage in the small intestine. The number of ways celiac disease can affect patients, combined with a lack of training in medical schools and primary care residency programs, contributes to the poor diagnosis rate. Currently it is estimated that 80% of the celiac disease population remains undiagnosed. Prevalence in Western Europe and in the United States ranges between 1 in 250 and 1 in 133. It is higher in relatives of people with celiac disease. Women are affected more commonly than men, but there is no age predilection. forecasts predict that the total prevalent cases of Celiac Disease is expected to accentuate up to 4.69 Million by 2023 at a Compound Annual Growth Rate (CAGR) of 0.46% from 2013-2023 while the diagnosed prevalent population of Celiac Disease in the 6MM shall grow at a CAGR of 0.15% for the forecast period (2013-2023).
- Scope of the Report
- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
- It focuses on the detailed historical and forecasted number of total prevalent cases as well as diagnosed prevalent cases of Celiac Disease for 6MM from 2013-2023.
- The Report also includes historical and forecasted Market size of Celiac Disease for 6MM from 2013 to 2023.
- It provides the information of available marketed therapies, including off-label biologics, patent and exclusivity details.
- The report also focuses on the details of pipeline drugs in the pivotal stage of development including their SWOT Analysis and expected launch date, which shall help to predict the impact of those drugs on the market size in the near future.
Purchase a copy of Celiac Disease (CD)-Market Insights, Epidemiology and Market Forecast-2023 @ http://www.orbisresearch.com/contact/purchase/209364 .
List Of Tables:
Table 1:Diagnosed Prevalent Cases of Celiac Disease in United States (2013-2023)
Table 2:Diagnosed Prevalent Cases of Celiac Disease in France (2013-2023)
Table 3:Diagnosed Prevalent Cases of Celiac Disease in Germany (2013-2023)
Table 4:Diagnosed Prevalent Cases of Celiac Disease in Italy (2013-2023)
Table 5:Diagnosed Prevalent Cases of Celiac Disease in Spain (2013-2023)
Table 6:Diagnosed Prevalent Cases of Celiac Disease in United Kingdom (2013-2023)
Table 7: Larazotide acetate, Clinical Trials by Zone, 2017
Table 8: Latiglutenase, Clinical Trials by Zone, 2017
Table 9: AMG 714, Clinical Trials by Zone, 2017
For any enquires before buying, connect with us @ email@example.com
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
For More Press Releases, visit: http://orbisnewsrelease.com/